CAS 476181-74-5: Golimumab

Description: Golimumab is a monoclonal antibody that specifically targets and inhibits tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various autoimmune diseases. It is primarily used in the treatment of conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Golimumab is produced through recombinant DNA technology and is administered via subcutaneous injection. The molecular structure of Golimumab consists of human IgG1κ isotype, which contributes to its stability and efficacy. Its mechanism of action involves binding to TNF-α, preventing it from interacting with its receptors, thereby reducing inflammation and modulating the immune response. The pharmacokinetics of Golimumab includes a relatively long half-life, allowing for less frequent dosing compared to some other TNF inhibitors. Common side effects may include injection site reactions, increased risk of infections, and potential allergic reactions. Overall, Golimumab represents a significant advancement in biologic therapies for chronic inflammatory conditions, offering patients improved management options.

Formula: Unspecified

Synonyms:

• CNTO 148
• Immunoglobulin G1, anti-(human tumor necrosis factor α) (human monoclonal CNTO 148 γ1-chain), disulfide with human monoclonal CNTO 148 κ-chain, dimer
• Simponi
• Simponi aria
• Golimumab

Golimumab CRS

CAS: 476181-74-5

Golimumab

CAS: 476181-74-5

Golimumab (CNTO-148), an anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anti-cancer activity, can be used …

• Color and Shape: Liquid
• Molecular weight: 146.93 kDa

Golimumab

CAS: 476181-74-5

A human IgG1 TNFα antagonist monoclonal antibody.